Opening book details…
Can I read Switching from Zoledronic Acid to Denosumab Increases the Risk for Developing Medication-related Osteonecrosis of the Jaw in Patients with Bone Metastases on EtoBox?
Switching from Zoledronic Acid to Denosumab Increases the Risk for Developing Medication-related Osteonecrosis of the Jaw in Patients with Bone Metastases by Hiroaki Ikesue; Kohei Doi; Mayu Morimoto; Masaki Hirabatake; Nobuyuki Muroi; Shinsuke Yamamoto; Toshihiko Takenobu; Tohru Hashida is a Medicine article available to read on EtoBox.
What is Switching from Zoledronic Acid to Denosumab Increases the Risk for Developing Medication-related Osteonecrosis of the Jaw in Patients with Bone Metastases about?
## Purpose Switch from zoledronic acid (ZA) to denosumab may increase the risk of medication-related osteonecrosis of the jaw (MRONJ) owing to the additive effect of denosumab on the jawbone and residual ZA activities. We evaluated the risk of developing MRONJ in patients who received ZA, denosumab, or ZA-to-denosumab for the treatment of bone metastases. ## Methods The medical charts of patients with cancer who received denosumab or ZA for bone metastases were retrospectively reviewed. Patients who did not undergo a dental examination at baseline were excluded. Primary endpoint was the evaluation of the risk of developing MRONJ in the ZA-to-denosumab group. Secondary endpoints were probability of MRONJ and the relationship between risk factors and the time to the development of MRONJ. ## Results Among the 795 patients included in this study, 65 (8.2%) developed MRONJ. The incidence of MRONJ was significantly higher in the ZA-to-denosumab group than in the ZA group [7/43 (16.3%) vs. 19/350 (5.4%), __p__ = 0.007]. Multivariate Cox proportional hazards regression analysis revealed that denosumab treatment [hazard ratio (HR), 2.41; 95% confidence interval (CI), 1.37–4.39; __p__ = 0.00
Who reads Switching from Zoledronic Acid to Denosumab Increases the Risk for Developing Medication-related Osteonecrosis of the Jaw in Patients with Bone Metastases?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Hiroaki Ikesue; Kohei Doi; Mayu Morimoto; Masaki Hirabatake; Nobuyuki Muroi; Shinsuke Yamamoto; Toshihiko Takenobu; Tohru Hashida
- Publisher
- Springer Science and Business Media LLC
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)